Skip to main content
S&P 5007,717.15+0.66%DOW51,132.33+0.40%NASDAQ27,163.47+1.09%BTC$84,688.00-0.26%ETH$2,683.89-0.75%GOLD$4,162.60-0.94%OIL$91.81-1.14%
Smart Investors Daily
SID Premium
RN

NASDAQ · RNTX

Rein Therapeutics Inc.

Healthcare · Medical - Pharmaceuticals

$0.85

Down-$0.05 (-5.50%)

Updated Oct 2, 2026, 5:40 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
40.22M
P/E ratio
-0.68
Dividend yield
0.00%
52-week range
$0.69 – $2.10
Volume
1.11M
Avg. volume
960.39K

Price performance · RNTX

RNTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

RNTX closed at $0.85 after 20 trading sessions, up 1.01% for the selected period.

Last close
$0.85
Period change
+1.01%
Period low
$0.70
Period high
$0.89
Daily close
View OHLC price history
RNTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$0.804$0.899$0.7588$0.85211.11M
Sep 30, 2026$0.80$0.8256$0.7624$0.804418.98K
Sep 29, 2026$0.7196$0.81$0.7196$0.79388.48K
Sep 28, 2026$0.7633$0.7898$0.72$0.721162.79K
Sep 25, 2026$0.7411$0.8199$0.7297$0.7484112.77K
Sep 24, 2026$0.77$0.7849$0.7145$0.744296.31K
Sep 23, 2026$0.79$0.8173$0.77$0.7703441.4K
Sep 22, 2026$0.807$0.8213$0.79$0.794787.14K
Sep 21, 2026$0.8106$0.8147$0.79$0.7945178.15K
Sep 18, 2026$0.7919$0.82$0.78$0.80492.49K
Sep 17, 2026$0.7154$0.7897$0.7025$0.7892262.7K
Sep 16, 2026$0.7101$0.74$0.70$0.7021266.51K
Sep 15, 2026$0.7843$0.79$0.7001$0.7075556.13K
Sep 14, 2026$0.8007$0.8454$0.75$0.791346.82K
Sep 11, 2026$0.7993$0.8132$0.7702$0.785295.57K
Sep 10, 2026$0.82$0.835$0.7717$0.7809240.77K
Sep 9, 2026$0.88$0.88$0.8221$0.8275265.27K
Sep 8, 2026$0.93$0.9598$0.85$0.8625763.81K
Sep 4, 2026$0.92$0.92$0.85$0.8891986.05K
Sep 3, 2026$0.79$0.87$0.79$0.8436568.11K

Latest RNTX news

The latest Smart Investors Daily articles mentioning RNTX.

Stock researchCompany · Overview

RNTX research

Overview

Company profile and research snapshot.

Company profile

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
RNTX recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Jul 20, 2026Maxim GroupBuy—
Jun 1, 2026HC Wainwright & Co.Buy—
Jan 21, 2026Brookline CapitalHold—
Sep 22, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and fibrosis indications, today announced that it will present a late-breaking poster at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain. Poster Presentation Title: Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation s

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By